Gilead Sciencesvs.Vertex Pharmaceuticals
GILD vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 1.3× larger than Vertex Pharmaceuticals by market cap.
Side by side
| GILD | VRTX | |
|---|---|---|
| Market cap | $170B | $135B |
| Price | $148.77 | $552.85 |
| Today | +1.4% | +1.0% |
| Return YTD | +19.6% | +20.8% |
| Return 1Y | +27.9% | +38.6% |
| P/E | — | 30.7 |
| P/S | 5.6 | 10.7 |
| P/B | 14.4 | 6.7 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Gilead SciencesGILD
HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.
Full GILD profile →Vertex PharmaceuticalsVRTX
Cystic fibrosis medicines carry the business. The newer work sits in pain treatment and in cell and gene therapy, where Casgevy belongs.
Full VRTX profile →More GILD & VRTX comparisons
Other head-to-heads in the Biotech & innovation segment.
See where GILD and VRTX sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →